Issues
Deals
Research
Ledger
About
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 23 · Tue 17 Nov
All issues
AbbVie
Every issue covering AbbVie.
1 issue
2026-09-22
No. 15
The CVR is an option, and Lilly holds it
DEALS
REGULATORY
TRIALS
LILLY
ATAIBECKLEY
COMPASS
ABBVIE
OTSUKA